Shanghai Hosts Nucleic Acid Drug R&D and Industrialization Summit – Forward to Claim Meal Voucher
Anlong
Gene Therapy Drug Developer
Nucleic Acid Drugs as a Cutting-Edge Field in Biopharmaceuticals: Showcasing Great Potential in Oncology and CNS Diseases with Unique Mechanisms of Action
Share this article link to Moments
No grouping and retain for more than 48 hours
Limited to 150 copies,Check in with Moments
Claim on the forwarding interface (Limited to 1)
(Note: Limited quantity, first come, first served)
Scan the code to register for free
List of Some Participating Companies in the Nucleic Acid Forum
Swipe to view more
The conference agenda is subject to the actual event, and more guest itineraries are being confirmed...
May 14
Co-organized by: PharmaCircle, Cytiva
AI Meets mRNA at Huizhengqi
Hui Aimin Hui Zhengqi Pharmaceuticals, Founder & Chairman & CEO
Innovative Technology-Driven Development of Next-Generation Small Nucleic Acid Drugs
Du ZhiqiangXuanjing Biotech, Chief Operating Officer
LNP-Delivered mRNA Innovative Drugs: Clinical Translation Practices from Tumor Vaccines to In Vivo CAR-T
Xiangrong SongWeisijin Bio, Co-Founder, PhD Supervisor at Sichuan University
Tea Break
Application of Antibody Conjugation to Enhance Extrhepatic Targeted Delivery of Small Nucleic Acid Drugs
Kong Hao Senior Scientist in Nucleic Acid Chemistry, GenScript Nanjing
Progress in the Development of Circular RNA Drugs
Tang Chenxiang Huanma Biotech, Chief Executive Officer
Roundtable: From PCC to IND — How to Efficiently Connect the R&D and CMC Ends?
Lu HangJiayi Bio CEO
Lin JiaqiNearby Biotech, Founder
Li XudongYisu Bio & Xilan Bio, Founder
Lunch Break
Key Process Challenges and Strategies in Oligonucleotide Drug CMC
Ruan QiankunCytiva China, Small Nucleic Acid Process Flow Manager
Application of Enzyme Catalysis Technology in the Synthesis of Nucleic Acid Drugs
Guest Itinerary Confirmation in Progress
Anlong Bio Small Nucleic Acid Drug Internationalization Strategy and Practice
Chunlin ZhaoAnlong, Founder
Application and Clinical Progress of mRNA Technology in the Development of Cancer Prevention and Treatment Drugs
Cen MountainRenjing Bio, Co-Founder & CSO
Tea Break
AI-Driven mRNA Therapy Development
Caiyi FeiChengshi Biomedical, Vice President & Co-Founder
Sirnaomics GalAhead Delivery Platform: Technical Features and Progress
Tian WeiweiSirnaomics, Vice President of R&D
Research on In Vivo Targeted Delivery of Novel Nucleic Acid Lipid Nanoparticles
Yang ZhenjunPeking University, Professor
Chemical Reactions and Quality Control in Oligonucleotide Synthesis
Feng BingSenior Director of Oligonucleotide R&D at Zhong肽 Biochemical
Application of Oligonucleotide Drugs in the Treatment of Chronic Diseases
Huang ZeaoYuekang Pharmaceuticals, Director of Small Nucleic Acid Development
*Sorted by the initials of names from A to Z, no special meaning.
30 Years of In-Depth Research in Virology: Basic Research in Virology and Experience in the Development and Production of Viral Vaccines and Drugs
A recognized scholar in the field of virology, with approximately 310+ publications in internationally renowned journals related to virology and drug development, and 70+ authorized patents.
Lead national 973, "Eleventh Five-Year Plan" "Twelfth Five-Year Plan" new drug creation and "Thirteenth Five-Year Plan" major science and technology projects for infectious diseases, national key R&D projects, Canadian AIDS Research Foundation, Canadian National Institutes of Health and other drug development projects.
Led the early research of more than ten mRNA drugs, including preventive vaccines for COVID-19, influenza, RSV, and therapeutic HPV vaccines, and carried out the development of multiple viral vaccines and drugs such as the anti-HIV drug IMB26 and the EV71 vaccine, obtaining two FDA approvals.
Professor and Researcher at the Institute of Medicinal Biotechnology, Peking Union Medical College
Dr. Du Zhiqiang (Danny) serves as the COO of the company, overseeing the development of the small nucleic acid innovative drug pipeline, improving and accelerating the industrialization process, and promoting international cooperation and enhancing the company's overall influence.
China Medical University 7-Year Combined Bachelor-Master Program in Clinical Medicine
Attending Physician at Shengjing Hospital Affiliated to China Medical University
Ph.D. in Biology, Texas Tech University, USA
Postdoctoral Fellow in Tumor Biology at MD Anderson Cancer Center, USA
Core R&D Role in Well-known MNC Pharmaceutical Companies
Vice President of R&D at a large listed pharmaceutical company in China
Dr. Du Zhiqiang has nearly 20 years of experience in drug research and development and industrial operation. He has held core R&D roles in well-known multinational pharmaceutical companies such as Novartis, Johnson & Johnson, and Amgen. In recent years, he served as the Vice President at Shanghai Renhui Biotechnology Co., Ltd. and Tonghua Dongbao Pharmaceutical Co., Ltd., two large listed companies in China, overseeing R&D. Dr. Du has extensive experience in pharmaceutical R&D, regulatory submissions, clinical medicine, industrial development, and corporate operations management, with particularly deep expertise and understanding in the field of chronic diseases.
Dr. Du Zhiqiang has joined Xuanjing Bio as COO and will primarily be responsible for: the R&D project initiation of the company's innovative pipeline and its forward-looking, strategic layout; leading the preclinical research, registration submissions, clinical development, and the connection and maintenance of related resources for the R&D pipeline; promoting and expanding the company’s international operations, cooperation, and development, among other critical tasks.
Chief Engineer of China's National Engineering Center for Nucleic Acid Drugs, and Sub-project Leader of the National Key Project "Innovative Research on Nucleic Acid Drug Varieties and Precision Modification and Novel Encapsulation Common Technologies (2017ZX09303013)." Currently serves as the Senior Director of the Oligonucleotide Division at Zhongpei Biotechnology Co., Ltd., mainly responsible for the construction of the nucleic acid pharmaceutical platform, establishment of oligonucleotide R&D and production teams, as well as project management and production.
Ph.D. in Bioinformatics from the University of Science and Technology of China, under the supervision of Professor Haiyan Liu. Has extensive research experience in molecular dynamics simulations, high-throughput sequencing, and artificial intelligence. Successfully developed multiple clinical high-throughput sequencing data analysis platforms. Published numerous papers in journals such as Science Advances and npj Vaccines, and obtained several authorized invention patents. As a co-founder of Chengshi Biotechnology, responsible for the identification, optimization, and clinical research of upstream targets for mRNA drugs. Led the team in developing platforms for systematic cross-species identification of cellular immune epitopes, humoral immune antigen design, and mRNA sequence optimization.
Former Executive President of Fosun Pharma, Global R&D President and Chief Medical Officer, Chairman of the Scientific Committee, and Fosun Global Partner. In early 2020, led the collaboration between Fosun Pharma and Germany's BioNTech, participating in the development of the world’s first mRNA COVID-19 vaccine, and directly oversaw the R&D and Greater China (including Hong Kong, Macao, and Taiwan) market launch of the vaccine Comirnaty, driving the growth of China’s mRNA industry. Directly led the global R&D and market launches of several blockbuster small molecule and biologic cancer drugs such as Ixazomib and Isatuximab, and spearheaded the China R&D and market launches of innovative drugs like Eltrombopag and Avatrombopag. In 2013, pioneered the clinical registration model of extending global Phase III clinical trials to China, setting a precedent for innovative drugs to be registered and marketed in China using global Phase III clinical data. Recipient of over 20 awards including the 4th Translational Medicine - International Cooperation Award and the International Young Scientist Award in Gastrointestinal Cancer. Authored more than 100 papers (published in The New England Journal of Medicine, The Lancet, Nature Medicine, etc.) and compiled eight monographs in Chinese, English, and Japanese. Formerly served as Global Vice President at Sanofi, Director of Shanghai Key Laboratory of Stem Cell Therapy, and Deputy Chair of the Oncology Committee of the China Pharmaceutical Innovation and Research Development Association.
Huang Zeao, Ph.D. graduate from the University of Chinese Academy of Sciences, is an associate researcher in biopharmaceuticals and an economist. He currently serves as the head of oligonucleotide therapy research and development at YooCare Pharmaceuticals, a member of the Drug Research and Development Professional Committee of the China Pharmaceutical Innovation and Research Promotion Association, an expert in the IFPMA ICH S13 working group, and a standing committee member of the Biomarker Professional Committee of the Chinese Research Hospital Association. He has published multiple first-author SCI papers in journals such as *Nature Communications*, *JACS*, and *Molecular Therapy Nucleic Acids*. He has been granted 36 authorized invention patents. In recent years, he has led new drug developments that have identified six PCCs, with two in Phase I clinical trials and two in Phase II clinical trials. The projects he has led or participated in have received seven U.S. IND approvals, six China IND approvals, and one Australian clinical trial authorization.
Lin Jiaqi, Professor at the School of Bioengineering, Dalian University of Technology, core member of the Ministry of Education's Key Laboratory of "Intelligent Biomanufacturing," and a national-level young talent. He received his bachelor's degree from Beihang University in 2005, and his Ph.D. in Biomedical Engineering (Nano-bio Interfaces) from Dalian University of Technology in 2012. From 2012 to 2018, he conducted postdoctoral research at the Massachusetts Institute of Technology (Nucleic Acid Drugs). From 2018 to 2020, he served as the R&D Director at BrainCo Inc. in the United States. He has been awarded the titles of Young Scientist by the Ministry of Science and Technology, Ningbo Yongjiang Talent, and Dalian Overseas High-Level Talent. His research focuses on mRNA drugs and vaccines, nano-bio interfaces, tissue engineering regeneration, and brain-computer interfaces. His research findings have been published in several international journals such as Science Translational Medicine, Nature Communications, Advanced Materials, Nano Letters, Materials Today, Science Advance, and Nano Today. Two of his papers were selected as ESI Highly Cited Papers, with citations exceeding 3600+ times and an h-index of 21. The significance of his research has gained widespread attention from peers both domestically and internationally, receiving positive reviews and coverage in Chemical Review, Chemical Society Review, Accounts of Chemical Research, Nature Reviews Drug Discovery, and Science Daily. As the principal investigator, he has undertaken key R&D projects for young scientists funded by the Ministry of Science and Technology, joint provincial science and technology projects, municipal "challenge-based" projects led by the Municipal Science and Technology Innovation Commission, and key municipal science and technology R&D plans, with a total vertical funding of 18 million yuan. He has applied for more than 20 invention patents in related fields, with 12 publicly disclosed, 5 authorized patents, and 3 achieving technology transfer.
Currently, a team of more than 40 people with interdisciplinary expertise in molecular biology, polymer chemistry, pharmaceutics, brain science, and artificial intelligence has been established at Dalian University of Technology. The team includes two associate professors, one senior engineer, one postdoctoral researcher, seven doctoral students, and more than 20 master's students. The team relies on the university’s Key Laboratory of Intelligent Biomanufacturing of the Ministry of Education and the State Key Laboratory of Fine Chemicals to carry out scientific innovation, talent cultivation, and team-building efforts.
Lu Hang is the CEO of Jiayi Bio, which focuses on the development and industrialization of innovative biopharmaceutical products based on mRNA technology and antibody platforms, and has established a development platform for preventive and therapeutic biological products.
Lu Hang has worked for over 20 years at EBSI and Merck in the United States, serving as Director or Chief Scientist, among other roles. As a technical leader or core team member, he has been responsible for multiple stages of the full lifecycle development of more than a dozen traditional and next-generation vaccines and biologics, including CYFENDUS, which received FDA approval for use in 2023.
Lu Hang is an advisor to the Vaccine Basic Research Professional Committee of the China Vaccine Industry Association and the former president of the Chinese Biopharmaceutical Association (CBA) in the United States.
Responsible for technical support of oligonucleotide projects across China, primarily serving leading domestic CDMOs, Biopharmas, and Biotechs in the oligonucleotide field. According to different customer needs, provides services such as oligonucleotide synthesis, upstream process development, technology transfer, and process scale-up. Since joining Cytiva, has successively supported pilot and commercial production projects for leading oligonucleotide companies including Asymchem, Pharma, CSPC, and Fujian Shengdi. Has extensive practical experience in implementing pilot and commercial-scale oligonucleotide projects.
Professor Xiangrong Song, Ph.D. in Pharmaceutics, Postdoctoral Fellow in Biology, Visiting Scholar in Nanomedicine and Immunology at Harvard Medical School, currently a Researcher/Doctoral Supervisor at the National Key Laboratory of Biotherapy, Sichuan University, selected as a National-level Young Talent, Chief Scientist of the National Key R&D Program, General Manager/Scientific Founder of WestGene Bio.
Engaged in the research and development of innovative drugs based on targeted delivery for nearly 20 years, published over 70 first-author/corresponding-author SCI papers in journals such as *Nat Nanotechnol*, *Nat Comm*, and *Sci Adv*. Filed 107 invention patent applications (including 29 international patents). The nano-adjuvant (WGa01) led by him has received Emergency Use Authorization (EUA) in China, and the Category 1 mRNA nano-new drug he led has obtained one Phase II clinical trial approval, four Phase I clinical trial approvals, with three entering clinical trial stages. In China, two small-molecule targeted drug clinical trial approvals have been obtained. He led the team to win the top prize (highest award) in the 2022 National Disruptive Technology Innovation Competition organized by the Ministry of Science and Technology. He serves as an editorial board member for journals such as *Sig Transduct Target Ther*, *Asian J Pharm Sci*, and *Eur J Pharm Sci*, a committee member of the Nucleic Acid Drug Branch of the Chinese Pharmaceutical Association, a youth committee member of the Pharmaceutics Special Committee of the Chinese Pharmaceutical Association, a committee member of the Nano Biotechnology Branch of the China Pharmaceutical Biotechnology Association, and the Chairman of the Western Innovation Center of the Sino-American Pharmaceutical Professionals Association (SAPA).
Dr. Tang Chenxiang is the Chief Executive Officer of Huanma Bio. He graduated from Tsinghua University with dual degrees in Biology and Economics, and obtained his Ph.D. from Yale University, where he conducted research on structural biology and biochemistry related to immunology. Dr. Tang has over a decade of experience in biochemistry and immunology as well as extensive management expertise. He has held positions such as Assistant to the President in multinational corporations and startups, and has published numerous high-quality SCI articles in top-tier journals. Prior to joining Huanma Bio, he founded Maijin Bio, a biopharmaceutical development platform under Hengrui Group, and served as its CEO, gaining substantial hands-on experience. Dr. Tang is a Professional Practice Professor at the MBA Center of Shanghai University, a member of the Tsinghua Entrepreneurs Association, and a member of the Pudong New Area Young Entrepreneurs Association. He has been honored with awards such as the Pudong New Area Mingzhu Leading Talent and the First Prize of the Pudong New Area "Mingzhu Cup" Entrepreneurship Competition.
Dr. Weiwei Tian currently serves as the Vice President of R&D at Sirnaomics Group and the General Manager of Sirnaomics (Suzhou). His research primarily focuses on the creation of novel small interfering RNA drugs and the development of delivery technologies. He earned his Ph.D. in Organic Chemistry from the University of Delaware, USA, and has conducted pharmaceutical-related research at The Scripps Research Institute (TSRI) in the United States and the Agency for Science, Technology and Research (A*STAR) in Singapore.
Professor at the School of Pharmaceutical Sciences, Peking University Health Science Center; Bachelor’s degree in Pharmacy and Ph.D. in Medicinal Chemistry from Beijing Medical University; Postdoctoral fellow at the College of Pharmacy, University of Georgia, USA. Formerly served as the Director of the Mobile Project of Chemical Biology at the National Natural Science Foundation of China and as the Associate Dean of the Department of Medicinal Chemistry at the same institution; currently serves as a member of the Medicinal Chemistry and Nucleic Acid Drugs Committee of the Chinese Pharmaceutical Association. Has long been engaged in research on chemical modifications of nucleic acid drugs and novel targeted formulations, led major special projects for new drug development, published over 160 papers, obtained more than 20 authorized patents, and received four awards from the Ministry of Education and the National Natural Science Award.
Founding Partner of Anlong Fund, Founder of Anlong. First graduating class of Tsinghua University’s Biology Department, Ph.D. in Molecular Biology from the University of Pittsburgh School of Medicine, MBA from the University of Chicago. Former Senior Manager at Pfizer US, Managing Director at CAS Star and CBC Group, with over thirty years of entrepreneurial and investment experience in life sciences and healthcare. Has invested in prominent companies such as Innovent Biologics, Berry Genomics, I-Mab, Ascletis Pharma, Laekna Therapeutics, Inmagene Biopharmaceuticals, and Guoke Hengtai. Served as the first Alumni Association President for Tsinghua University's School of Life Sciences, School of Medicine, and School of Pharmaceutical Sciences; senior member of BayHelix. Outside of his profession, he enjoys football and skiing, used to be a DJ, and has three beautiful and adorable daughters. Anlong Fund is an investment fund focused on early-stage life sciences and healthcare in China, spanning areas such as life sciences, pharmaceutical R&D, medical devices, healthcare services, and related fields. Anlong is a leading Chinese nucleic acid drug company, specializing in new drug research and development in gene therapy, RNA, and gene editing.
Scan the code to register for free
Ms. Zhou 13306586060
Ms. Ji 15706844213
Ms. Jin 15158066904
Ms. Xue 15958675001
Mr. Hong 19957626573
Scan the code to register for free attendance